206 related articles for article (PubMed ID: 36980643)
1. Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study.
Macedo LT; Costa EFD; Carvalho BF; Lourenço GJ; Calonga L; Castilho AM; Chone CT; Lima CSP
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980643
[TBL] [Abstract][Full Text] [Related]
2. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract][Full Text] [Related]
3. Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients.
Ferreira AMC; Altemani JMC; Macedo LT; Lourenço GJ; Lima CSP
Sci Rep; 2023 Oct; 13(1):16762. PubMed ID: 37798436
[TBL] [Abstract][Full Text] [Related]
4. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients.
Nogueira GAS; Costa EFD; Lopes-Aguiar L; Lima TRP; Visacri MB; Pincinato EC; Lourenço GJ; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
Oncotarget; 2018 Jul; 9(51):29538-29547. PubMed ID: 30038702
[TBL] [Abstract][Full Text] [Related]
6. GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Pincinato EC; Costa EFD; Lopes-Aguiar L; Nogueira GAS; Lima TRP; Visacri MB; Costa APL; Lourenço GJ; Calonga L; Mariano FV; Altemani AMAM; Coutinho-Camillo C; Chone CT; Ramos CD; Altemani JMC; Moriel P; Lima CSP
Sci Rep; 2019 Jun; 9(1):9312. PubMed ID: 31249357
[TBL] [Abstract][Full Text] [Related]
7.
Costa EFD; Lima TRP; Lopes-Aguiar L; Nogueira GAS; Visacri MB; Quintanilha JCF; Pincinato EC; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
Tumour Biol; 2020 Jul; 42(7):1010428320938494. PubMed ID: 32628088
[TBL] [Abstract][Full Text] [Related]
8. Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma.
Nogueira GA; Lourenço GJ; Oliveira CB; Marson FA; Lopes-Aguiar L; Costa EF; Lima TR; Liutti VT; Leal F; Santos VC; Rinck-Junior JA; Lima CS
Int J Cancer; 2015 Aug; 137(4):810-8. PubMed ID: 25598504
[TBL] [Abstract][Full Text] [Related]
9. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
Psyrri A; Gkotzamanidou M; Papaxoinis G; Krikoni L; Economopoulou P; Kotsantis I; Anastasiou M; Souliotis VL
ESMO Open; 2021 Apr; 6(2):100075. PubMed ID: 33714009
[TBL] [Abstract][Full Text] [Related]
10. Do genetic polymorphisms modulate response rate and toxicity of Cisplatin associated with radiotherapy in laryngeal squamous cell carcinoma?: a case report.
Lopes-Aguiar L; Visacri MB; Nourani CML; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Moriel P; Altemani JMC; Lima CSP
Medicine (Baltimore); 2015 Apr; 94(16):e578. PubMed ID: 25906090
[TBL] [Abstract][Full Text] [Related]
11. Influence of CASP9 c.-1339A>G and CASP3 c.-1191A>G variants in outcome of patients with head and neck squamous cell carcinoma.
Carvalho BF; Costa EFD; Lopes-Aguiar L; Liutti VT; Leal F; Vasconcelos VCA; Rinck-Junior JA; Lourenço GJ; Lima CSP
J Oral Pathol Med; 2020 Nov; 49(10):1078-1083. PubMed ID: 32816327
[TBL] [Abstract][Full Text] [Related]
12. GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs.
Budai B; Prekopp P; Noszek L; Kovács ER; Szőnyi M; Erdélyi DJ; Bíró K; Géczi L
J Mol Med (Berl); 2020 Jul; 98(7):963-971. PubMed ID: 32435918
[TBL] [Abstract][Full Text] [Related]
13. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
[TBL] [Abstract][Full Text] [Related]
14. Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association.
Sherief LM; Rifky E; Attia M; Ahmed R; Kamal NM; Oshi MAM; Hanna D
Medicine (Baltimore); 2022 Nov; 101(45):e31627. PubMed ID: 36397425
[TBL] [Abstract][Full Text] [Related]
15. Gstm1/Gstt1 is essential for reducing cisplatin ototoxicity in CBA/CaJ mice.
Li P; Liu Z; Wang J; Bi X; Xiao Y; Qiao R; Zhou X; Guo S; Wan P; Chang M; Hong G; Liu Z; Ming X; Gao J; Fu X
FASEB J; 2022 Jun; 36(6):e22373. PubMed ID: 35621716
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
[TBL] [Abstract][Full Text] [Related]
18. Association between genetic polymorphisms and platinum-induced ototoxicity in children.
Lui G; Bouazza N; Denoyelle F; Moine M; Brugières L; Chastagner P; Corradini N; Entz-Werle N; Vérité C; Landmanparker J; Sudour-Bonnange H; Pasquet M; Verschuur A; Faure-Conter C; Doz F; Tréluyer JM
Oncotarget; 2018 Jul; 9(56):30883-30893. PubMed ID: 30112115
[TBL] [Abstract][Full Text] [Related]
19. Ototoxicity from combined Cisplatin and radiation treatment: an in vitro study.
Low WK; Kong SW; Tan MG
Int J Otolaryngol; 2010; 2010():523976. PubMed ID: 21151649
[TBL] [Abstract][Full Text] [Related]
20. [Genetic background of cisplatin induced ototoxicity].
Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
